Until now, the majority of African countries have been dependent on importing medicines for population healthcare. In this opinion piece, Dr Arnaud Kaboré, pharmacist and engineer, proposes a roadmap for public decision-makers to achieve African health sovereignty by 2045.
A dependency that has become a health risk
Even today, fewer than five African countries have manufacturing units capable of exporting outside their region. The result: the continent still imports 94 percent of medicines at an annual cost exceeding 18 billion dollars—a figure that could exceed 30 billion by 2030 (IFC, 2022). But beyond the economic impact, these figures reveal deep structural dependency and health vulnerability.
More than 70 percent of public health facilities in Africa report experiencing at least one critical stock shortage per quarter (WHO, 2023). Is it acceptable that the health of 1.4 billion Africans depends almost entirely on industrial, logistical, and geopolitical decisions made outside the continent? The Covid-19 pandemic, recurring shortages of essential medicines such as amoxicillin, insulin, or anaesthetics, and chronic lack of access to cancer treatments or innovative therapies carry enormous human cost: poorly treated diseases, prices tripled during supply tensions, and public health programmes paralysed for lack of available treatments. Yet Africa has significant advantages:
- An expanding market: the African pharmaceutical sector could exceed 70 billion dollars by 2030 (McKinsey, 2022);
- Exceptional biodiversity: more than 5,400 medicinal plants recorded, some already integrated into official therapeutic protocols (African Union);
- Growing regulatory momentum: with the African Medicines Agency (AMA), ratified by 27 countries, harmonisation of standards is becoming reality;
- Affirmed political will: countries such as Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa have launched ambitious local production programmes.
Reinventing African health: the African path to a sustainable pharmaceutical industry
One of the major historical errors was attempting to reproduce the international "Big Pharma" model without mastering its foundations or value chain. Yet an industry cannot be copied and cannot be invented on paper: it is built patiently, by first consolidating the most accessible and most strategic segments.
For years, the approach was limited to investing in imported equipment, without simultaneously developing human skills, technical expertise, and local industrial assets. This model inevitably leads to local production that costs more than medicine imports, persistent dependency on raw materials, technologies, and expertise, and failure of health sovereignty ambitions. Pharmaceutical industrialisation in Africa cannot avoid the rigour, methodology, and long-term vision required by a sector as vital and complex as this one.
It is therefore essential to clarify the determinants of this industrialisation in order to build a coherent strategy, rooted in the continent's endogenous needs and based on its own strengths: growing market, medicinal biodiversity, regulatory momentum, and affirmed political will. This opinion piece aims to propose a clear and pragmatic roadmap to public decision-makers for reclaiming African health sovereignty by 2045. Our health, our industry. Pharmaceutical industrialisation in Africa must be part of a broader continent-wide industrialisation strategy, driven by clear vision, appropriate means, and unwavering political will. Produce here to heal here. And tomorrow, heal the world.
Dr Arnaud Kaboré Pharmacist Engineer and senior executive in the health sector
References and sources
- WHO – Report on the state of pharmaceutical production in Africa, 2023.
- IFC & World Bank – Pharmaceutical Manufacturing in Africa, 2022.
- McKinsey – Africa Pharma 2030, 2022.
- Africa CDC – African Medicines Agency Status Report, 2024.
- African Union – Strategy for the African pharmacopoeia, 2021.
- UNIDO – Industrial development in Sub-Saharan Africa, 2023.
- African Development Bank – Health and Pharma Outlook, 2024.
